Blog Posts

Mark Lythgoe

Apr 14, 2025, 11:06

Mark Lythgoe: Do we need to re-evaluate the clinical utility of how we measure PDL1?

Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared a post on X:

“Not all PDL1 assays are the same in bladder cancer – important work. do we need to re-evaluate the clinical utility of how we measure PDL1 and does this have implications for other cancers???”

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer

Authors: Matthew D. Galsky et al.

Mark Lythgoe

Aristotelis Bamias cancer Deepali Rishipathak Eiji Kikuchi Enrique Grande Hartmut Koeppen Ian D. Davis Ira Mellman Jonathan F. Anker Jose Angel Arranz Juliette Roels Justin M. David Kobe Yuen Maria De Santis Mark Kockx Mark Lythgoe Matthew D. Galsky Maureen Peterson OncoDaily Oncology Patrick Williams Robert J. Johnston Romain Banchereau Roos Van Elzen Sacha Gnjatic Sandrine Bernhard Sanjeev Mariathasan Saurabh Gupta Shomyseh Sanjabi Sudeh Izadmehr Xiangnan Guan

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...